Focus: DiaMedica Therapeutics is a public biotech company developing biologic therapeutics for neurology, nephrology, and metabolic diseases. The company is pre-revenue and focused on advancing a pipeline of recombinant protein and small molecule programs through early-stage clinical development.
Profile data last refreshed 15h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow DiaMedica Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for DiaMedica Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from DiaMedica Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 - Business Wire
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 Business Wire
DiaMedica Therapeutics (NASDAQ: DMAC) investors approve directors, pay and 3.5M-share incentive plan boost - Stock Titan
DiaMedica Therapeutics (NASDAQ: DMAC) investors approve directors, pay and 3.5M-share incentive plan boost Stock Titan
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial Business Wire
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - BioSpace
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference BioSpace
DiaMedica CEO to speak in NYC; company targets stroke, preeclampsia - Stock Titan
DiaMedica CEO to speak in NYC; company targets stroke, preeclampsia Stock Titan
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2026 Earnings Call Transcript - Insider Monkey
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2026 Earnings Call Transcript Insider Monkey
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo